Biotech

Theralase Technologies announced a fourth patient was treated with the photo dynamic therapy for non-muscle invasive bladder cancer.

Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) announced a fourth patient was treated with the photo dynamic therapy for non-muscle invasive bladder cancer.
As quoted in the press release:

These patients come from a population that has failed standard of care and have remained drug resistant after the standard first line Bacillus Calmette Guérin (“BCG“) course of treatments.
The Phase Ib NMIBC clinical study (“Study“) is entitled, “A Phase Ib Trial of Intravesical Photodynamic Therapy in Patients with Non-Muscle Invasive Bladder Cancer at High Risk of Progression Who are Refractory to Therapy with Bacillus Calmette-Guérin (“BCG“) and Who are Medically Unfit for or Refuse a Cystectomy.”
The PDT treatment procedure involves the instillation of a water-based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow localization of the PDC to the NMIBC. The bladder is then drained of the solution, flushed with sterile water to remove excess solution and refilled with sterile water via a cystoscope. At this point, a fibre optic assembly, with the ability to both emit and detect laser light, is inserted through the cystoscope, to activate the PDC.

Click here to read the full press release.

Source: www.accesswire.com

Featured

MARKETS

Markets
TSX20744.23+53.42
TSXV808.73-3.59
DOW33301.93+61.75
S&P 5004183.96+8.76
NASD12488.93-1.81
ASX7261.20-56.80

COMMODITIES

Commodities
Gold1880.33-5.43
Silver23.21-0.12
Copper4.45-0.02
Palladium2232.00+22.00
Platinum916.50-0.50
Oil100.52-1.50
Heating Oil3.940.00
Natural Gas7.36+0.02

DOWNLOAD FREE REPORTS

×